Histamine-3 Receptor Antagonists

A method of treatment of a disorder or condition selected from the list consisting of acute myocardial infarction;

• anxiety;
• dementia;
• cognition disorders such as Alzheimer's disease;
• attention deficit disorder (ADD);
• attention-deficit hyperactivity disorder (ADHD);
• cancers (including cutaneous carcinoma, medullary thyroid carcinoma and melanoma);
• memory processes disorders;
• depression;
• manic-depressive disorder;
• epilepsy;
• Meniere's disease;
• gastrointestinal disorders;
• inflammation;
• migraine;
• motion sickness;
• obesity;
• pain;
• Parkinson's disease;
• schizophrenia;
• sleep disorders;
• septic shock;
• respiratory disorders (including allergic rhinitis, nasal congestion and allergic congestion) in a mammal, including a human, the method comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound of the formula (I):
• or a pharmaceutically acceptable salt thereof, wherein:
• X1 is a group of the formula:
• —(CH2)m—NR5R6
• X2 is H, Cl, or F;
• R1 and R2 are independently hydrogen or methyl;
• R3 is hydrogen or methyl;
• m is one;
• n is zero, one or two;
• R5 is independently (C1-C6)-alkyl, aryl, (C1-C3)-alkyl-aryl, each alkyl or aryl being optionally substituted at available positions by alkyl, CF3, OH, CN and halogen;
• R6 is independently H, (C1-C6)-alkyl, aryl, (C1-C3)-alkyl-aryl, each alkyl or aryl being optionally substituted at available positions by alkyl, CF3, OH, CN and halogen;
• or
• NR5R6 is a 5- to 12-membered monocyclic ring containing up to 3 heteroatoms selected from O, S and N;
• or a 6- to 12-membered bicyclic ring system containing up to 4 heteroatoms selected from O, S and N;
• or a 10- to 18-membered tricyclic ring system containing up to 5 heteroatoms selected from O, S and N;
• each of these cyclic ring systems optionally substituted at available positions by (C1-C6)-alkyl, aryl, heteroaryl, OH, CF3, and O—(C1-C6)alkyl.